Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium.

Abstract: A water-dispersible tablet comprises acyclovir and a dispersing agent. The dispersing agent is a swellable clay such as a smectite e.g., Veegum F or bentonite, and is present within the granules of the tablet to provide a tablet which is capable of dispersing in water within 3 minutes to provide a dispersion which will pass through a 710 .mu.m sieve. The tablet also includes a cellulostic excipient. The tablet can be optionally film-coated, in which case the dispersion time is less than 5 minutes.

Abstract: The present invention provides polypeptides of the formula XX.sup.1 TrpX.sup.2 X.sup.3 X.sup.4 X.sup.5 X.sup.6 X.sup.7 NH.sub.2, methods of treatment using the polypeptides, pharmaceutical compositions comprising such polypeptides, and processes for their preparation. The polypeptides possess antagonist properties against bombesin and bombesin-like peptides and are useful in the treatment of malignant disease. M, X, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, X.sup.6, and X.sup.7 are as defined in the specification.

Abstract: An automated biological cell harvesting apparatus including a fluid dispensing head adapted to move to a lowered position and dispense fluid from a plurality of spray ports, a fixed upper tray positioned beneath the fluid dispensing head for supporting a biological filter plate of the type defining a plurality of fluid permeable wells therein, a vertically movable lower tray adapted to move from a lowermost position to a raised position in engagement with the upper tray. A controller is provided for dispensing fluid from the fluid dispensing head into the wells of the filter plate, and raising the lower tray into its raised position in engagement with the upper tray and then creating a vacuum between the lower tray and the upper tray to draw the fluid from the filter plate supported on the upper tray into the lower tray for collection in a microplate with a corresponding number of wells or, in the absence of a microplate, for removal of the fluid from the lower tray to a remote common waste collection vessel.

Abstract: Compounds of formula (I) wherein n is 0, 1 or 2; and R.sup.1 and R.sup.2, which may be the same or different, each represent one or more ring substituent(s) selected from: hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); --NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5, which may be the same or different, each represent hydrogen or C.sub.1-6 alkyl; --S(O).sub.m R.sup.6, where m is 0, 1, 2 or 3 and R.sup.6 represents hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloakyl; --SO.sub.2 NR.sup.4 R.sup.5 where R.sup.4 et R.sup.5 are each as defined above; phenyl, phenylC.sub.1-3 alkoxy or phenylC.sub.1-3 alkyl where the phenyl group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and --CO.sub.2 H or --COR.sup.7 where R.sup.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: Compounds of formula (I) wherein n is 0, 1 or 2; and R.sup.1 and R.sup.2, which may be the same or different, each represent one or more ring substituent(s) selected from: hydroxy, halogen, cyano, nitro, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); --NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 which may be the same or different, each represent hydrogen or C.sub.1-6 are each as defined above; phenyl, phenyl C.sub.1-3 alkoxy or phenyl C.sub.1-3 alkyl where the phenyl group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and --CO.sub.2 H or --COR.sup.7 where R.sup.7 is C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is hydrogen or C.sub.

Abstract: A fusion protein suitable for use as a vaccine comprises an amino acid sequence having biological activity which is fused via an intervening hinge comprising from two to eight glycine-proline repeats to the C-terminus of sufficient of the amino acid sequence of a B subunit of an enterotoxin which is capable of ADP-ribosylation of a GTPase.

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Abstract: The present invention relates to compounds of general formula (I) ##STR1## and physiologically acceptable salts thereof wherein the group NR.sub.1 R.sub.2 represents a 5-7 membered saturated heterocyclic ring which may be substituted by one or two methyl groups; R.sub.3 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or phenyl optionally substituted by 1 or 2 halogen atoms; R.sub.4 is phenyl or phenyl substituted by one or two groups selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, trifluoromethoxy or (CH.sub.2).sub.n R.sub.5 wherein n is zero or 1 and R.sub.5 represents C.sub.1-4 alkoxy, hydroxy, nitro, cyano, CO.sub.2 R.sub.6, S(O).sub.p CH.sub.3, NR.sub.7 R.sub.8, CONR.sub.7 R.sub.8, SO.sub.2 NR.sub.7 CO(C.sub.1-4)alkyl, tetrazolyl, carboxamidotetrazolyl, or a 3-trifluoromethyl 1,2,4-triazolyl; R.sub.6 is hydrogen, C.sub.1-4 alkyl or benzyl; R.sub.7 is hydrogen or C.sub.1-4 alkyl, R.sub.8 is hydrogen, C.sub.1-4 alkyl, SO.sub.2 CH.sub.3 or SO.sub.2 CF.sub.3, X represent hydrogen, C.

Abstract: The present invention discloses a method for inhibiting tissue damage in mammals caused by pathological NO production, which comprises administering an effective tissue damage inhibition amount of a NO synthase inhibitor to said mammal. Preferably the NO synthase inhibitor is L-NMMA.

Abstract: The compound 1,8-diazabicyclo[5.4.0]undec-1(7)-enium cyanide is the reaction product of acetone cyanohydrin and 1,8-diazabicyclo [5.4.0]undec-7-ene.

Abstract: A method for treating HIV infections comprising administering a composition whose active ingredient is 2',3'-dideoxy-3'-fluoro-5'-chlorouridine.

Abstract: The present invention relates to the use of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other physiologically functional derivative thereof for the manufacture of a medicament for the treatment of tumours in animals, to pharmaceutical compositions for the treatment of tumours in animals, to pharmaceutical compositions for the treatment of tumours, comprising said compound as active ingredient and to a method of treating tumours in an animal which comprises administering to said animal an effective amount of said compound.

Abstract: The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.

Abstract: The present invention relates to pharmaceutical compositions for the treatment of infections caused by Microsporidia comprising treating an animal with 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt thereof.

Abstract: The present invention relates to certain 2',3'-dideoxynucleosides and pharmaceutically acceptable derivatives thereof, methods for preparing them, their use in the treatment and prophylaxis of viral, especially retroviral, infections, and pharmaceutical formulations containing them.

Abstract: The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of protozoal infections caused by Kinetoplastida, Apicomplexa, Anaerobic protozoa and Mircosporidia comprising 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other functional derivative thereof as active ingredient and to a method of treating or preventing siad protozoal infections in an animal which comprises administering to said animal an effective amount of siad compound.

Abstract: The present invention relates to water soluble, camptothecin derivatives of formula (I), ##STR1## wherein: 1) R.sup.1 and R.sup.2 represent independently, hydrogen, lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy lower alkyl;ii) R.sup.1 represents hydrogen, lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl or lower alkoxy lower alkyl, and R.sup.2 represents --COR.sup.3,wherein:R.sup.3 represents hydrogen, lower alkyl, perhalo-lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy or lower alkoxy lower alkyl; oriii) R.sup.1 and R.sup.2 taken together with the linking nitrogen form a saturated 3 to 7 atom heterocyclic group of formula (IA) ##STR2## wherein: Y represents O, S, SO, SO.sub.2, CH.sub.2 or NR.sup.4wherein:R.sup.

Abstract: A water-dispersible tablet comprises lamotrigine, a pharmaceutically acceptable swellable clay and an additional disintegrating agent. The swellable clay and an additional disintegrating agent. The swellable clay is a smectite, e.g. Veegum F or bentonite, and is present within the granules of the tablet to provide a tablet which is capable of dispersing in water within 3 minutes to provide a dispersion which will pass through a 710 .mu.m sieve. The tablet can be optionally film-coated in which case the dispersion time is less than 5 minutes.